Who are Intracervical injection of Vasopressin's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): DDAVP Inhalant Product, Norepinephrine and Vasopressin for Rescue, vasopressin - early initiation, Angiotensin II Infusion, low-dose epinephrine and tranexamic acid, Vasopressin, Arginine.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/intracervical-injection-of-vasopressin.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-18 · How we verify

Intracervical injection of Vasopressin — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Intracervical injection of Vasopressin (Intracervical injection of Vasopressin) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Vasopressor agent. Area: Gynecology.

marketed Vasopressor agent V1 vasopressin receptor Gynecology Small molecule Live · refreshed every 30 min

Target snapshot

Intracervical injection of Vasopressin (Intracervical injection of Vasopressin) — Prisma Health-Upstate. Vasopressin acts as a vasoconstrictor that reduces bleeding by constricting blood vessels in the cervix when injected directly into cervical tissue.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Intracervical injection of Vasopressin TARGET	Intracervical injection of Vasopressin	Prisma Health-Upstate	marketed	Vasopressor agent	V1 vasopressin receptor
DDAVP Inhalant Product	DDAVP Inhalant Product	Nationwide Children's Hospital	marketed	Vasopressin analog; antidiuretic agent	V2 vasopressin receptor; V1 vasopressin receptor
Norepinephrine and Vasopressin for Rescue	Norepinephrine and Vasopressin for Rescue	Hospital do Coracao	phase 3	Vasopressor combination	Alpha-1 adrenergic receptor, beta-1 adrenergic receptor, V1 vasopressin receptor
vasopressin - early initiation	vasopressin - early initiation	The Cleveland Clinic	marketed	Vasopressor agent	Vasopressin receptor (V1 and V2)
Angiotensin II Infusion	Angiotensin II Infusion	Massachusetts General Hospital	marketed	Vasopressor agent	Angiotensin II receptor (AT1 and AT2)
low-dose epinephrine and tranexamic acid	low-dose epinephrine and tranexamic acid	King Abdullah International Medical Research Center	marketed	Combination hemostatic and vasopressor agent	Alpha-1 and beta-1 adrenergic receptors (epinephrine); plasminogen and plasmin (tranexamic acid)
Vasopressin, Arginine	Vasopressin, Arginine	Lars Wiuff Andersen	marketed	Vasopressor agent; antidiuretic hormone	Vasopressin receptors (V1a, V1b, V2)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Vasopressor agent class)

Assistance Publique - Hôpitaux de Paris · 1 drug in this class
Hospital do Coracao · 1 drug in this class
Massachusetts General Hospital · 1 drug in this class
Prisma Health-Upstate · 1 drug in this class
The Cleveland Clinic · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Intracervical injection of Vasopressin — Competitive Intelligence Brief. https://druglandscape.com/ci/intracervical-injection-of-vasopressin. Accessed 2026-05-18.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab